Georgia Beasley

Positions:

Associate Professor of Surgery

Surgical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

B.A. 2001

Duke University

M.D. 2008

Duke University School of Medicine

M.H.S. 2012

Duke University

General Surgery Resident, Surgery

Duke University

Surgical Oncology Fellow, Surgery

Ohio State University

Grants:

A Phase I trial of PVSRIPO for Patients with Unresectable Melanoma

Administered By
Duke Cancer Institute
Awarded By
Istari Oncology
Role
Principal Investigator
Start Date
End Date

A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma

Administered By
Duke Cancer Institute
Awarded By
Delcath Systems, Inc.
Role
Principal Investigator
Start Date
End Date

Comprehensive immunologic profiling of the sentinel node to optimize care for patients with melanoma

Administered By
Surgical Oncology
Awarded By
Society of Surgical Oncology
Role
Principal Investigator
Start Date
End Date

OMS-I103 / PICSES

Administered By
Duke Cancer Institute
Awarded By
OncoSec Medical
Role
Principal Investigator
Start Date
End Date

Replimune RPL-001-16

Administered By
Duke Cancer Institute
Awarded By
Replimune Group, INC
Role
Principal Investigator
Start Date
End Date

Publications:

Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma.

BACKGROUND: Sentinel lymph node biopsy (SLNB) is routinely recommended for clinically localized Merkel cell carcinoma (MCC); however, predictors of false negative (FN) SLNB are undefined. METHODS: Patients from six centers undergoing wide excision and SLNB for stage I/II MCC (2005-2020) were identified and were classified as having either a true positive (TP), true negative (TN) or FN SLNB. Predictors of FN SLNB were identified and survival outcomes were estimated. RESULTS: Of 525 patients, 28 (5.4%), 329 (62.7%), and 168 (32%) were classified as FN, TN, and TP, respectively, giving an FN rate of 14.3% and negative predictive value of 92.2% for SLNB. Median follow-up for SLNB-negative patients was 27 months, and median time to nodal recurrence for FN patients was 7 months. Male sex (hazard ratio [HR] 3.15, p = 0.034) and lymphovascular invasion (LVI) (HR 2.22, p = 0.048) significantly correlated with FN, and increasing age trended toward significance (HR 1.04, p = 0.067). The 3-year regional nodal recurrence-free survival for males >75 years with LVI was 78.5% versus 97.4% for females ≤75 years without LVI (p = 0.009). Five-year disease-specific survival (90.9% TN vs. 51.3% FN, p < 0.001) and overall survival (69.9% TN vs. 48.1% FN, p = 0.035) were significantly worse for FN patients. CONCLUSION: Failure to detect regional nodal microscopic disease by SLNB is associated with worse survival in clinically localized MCC. Males, patients >75 years, and those with LVI may be at increased risk for FN SLNB. Consideration of increased nodal surveillance following negative SLNB in these high-risk patients may aid in early identification of regional nodal recurrences.
Authors
Straker, RJ; Carr, MJ; Sinnamon, AJ; Shannon, AB; Sun, J; Landa, K; Baecher, KM; Wood, C; Lynch, K; Bartels, HG; Panchaud, R; Lowe, MC; Slingluff, CL; Jameson, MJ; Tsai, K; Faries, MB; Beasley, GM; Sondak, V; Karakousis, GC; Zager, JS; Miura, JT
MLA Citation
Straker, Richard J., et al. “Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma.Ann Surg Oncol, vol. 28, no. 12, Nov. 2021, pp. 6995–7003. Pubmed, doi:10.1245/s10434-021-10031-z.
URI
https://scholars.duke.edu/individual/pub1485076
PMID
33890195
Source
pubmed
Published In
Annals of Surgical Oncology
Volume
28
Published Date
Start Page
6995
End Page
7003
DOI
10.1245/s10434-021-10031-z

Trends in Racial, Ethnic, and Sex Representation Among Surgical Faculty Members and Medical Students in the US, 2011-2020.

Authors
Yu, AYL; Iwai, Y; Thomas, SM; Beasley, GM; Sudan, R; Fayanju, OM
MLA Citation
Yu, Alice Yunzi L., et al. “Trends in Racial, Ethnic, and Sex Representation Among Surgical Faculty Members and Medical Students in the US, 2011-2020.Jama Surg, Oct. 2021. Pubmed, doi:10.1001/jamasurg.2021.4904.
URI
https://scholars.duke.edu/individual/pub1499780
PMID
34689187
Source
pubmed
Published In
Jama Surg
Published Date
DOI
10.1001/jamasurg.2021.4904

Potential Utility of Synthetic D-Lactate Polymers in Skin Cancer

Authors
Dikshit, A; Lu, J; Ford, AE; Degan, S; Jin, YJ; Sun, H; Nichols, A; Salama, AKS; Beasley, G; Gooden, D; Zhang, JY
MLA Citation
Dikshit, Anushka, et al. “Potential Utility of Synthetic D-Lactate Polymers in Skin Cancer.” Jid Innovations, vol. 1, no. 3, Elsevier BV, Sept. 2021, pp. 100043–100043. Crossref, doi:10.1016/j.xjidi.2021.100043.
URI
https://scholars.duke.edu/individual/pub1494974
Source
crossref
Published In
Jid Innovations
Volume
1
Published Date
Start Page
100043
End Page
100043
DOI
10.1016/j.xjidi.2021.100043

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.

This review describes the current body of literature and ongoing clinical trials examining neoadjuvant immune checkpoint inhibitors (ICI) for patients with resectable stage III and IV melanoma. Based on prior success in treating metastatic melanoma and as adjuvant therapy, ICIs are being explored in the neoadjuvant setting. There have been initial trials and there are many ongoing trials examining neoadjuvant ICI. Herein, we will review the clinical feasibility and efficacy of various neoadjuvant ICI regimens, explore pathologic and cellular responses, and present factors associated with predictive tumor response.
Authors
Sarver, M; Brown, MC; Rhodin, KE; Salama, AKS; Beasley, GM
MLA Citation
Sarver, Melissa, et al. “Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.Hum Vaccin Immunother, July 2021, pp. 1–9. Pubmed, doi:10.1080/21645515.2021.1943987.
URI
https://scholars.duke.edu/individual/pub1489122
PMID
34254900
Source
pubmed
Published In
Hum Vaccin Immunother
Published Date
Start Page
1
End Page
9
DOI
10.1080/21645515.2021.1943987

Correction to: The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma.

Authors
Lee, AY; Friedman, EB; Sun, J; Potdar, A; Daou, H; Farrow, NE; Farley, CR; Vetto, JT; Han, D; Tariq, M; Shapiro, R; Beasley, G; Contreras, CM; Osman, I; Lowe, M; Zager, JS; Berman, RS
MLA Citation
Lee, Ann Y., et al. “Correction to: The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma.Ann Surg Oncol, Apr. 2021. Pubmed, doi:10.1245/s10434-021-10047-5.
URI
https://scholars.duke.edu/individual/pub1482309
PMID
33893602
Source
pubmed
Published In
Annals of Surgical Oncology
Published Date
DOI
10.1245/s10434-021-10047-5